Dominic D'Agostino

Looks exactly like a CGM device.

Uses essentially the same technology, just a different enzyme.

I could swim all day in salt water.

I can do stuff on the farm.

I don't knock it off.

It's like probably as reliable as a CGM device is now.

It's remarkably reliable.

The specificity is good.

And it's BHB?

It's beta-hydroxybutyrate.

Yeah, it's important to acknowledge that it's the D enantiomer or the R enantiomer of BHB because there's supplements out there that are racemix.

But yeah, I've tested it, pressure tested it, if you will, with high doses of ketones and it performs well.

And so there's emerging technologies.

So the continuous ketone monitor, continuous lactate monitor, which is, I think it's going to be lactates and oncometabolites.

Not commercially ready yet.

There's programs, but I don't think monetarily, I don't think the companies are motivated to bring it to market.

And I think there's some more testing that needs to be done.

But for example, my colleagues at the Moffitt Cancer Center, they're like salivating over the opportunity to do glucose ketone and lactate monitoring, especially.

We see that tumor burden is tightly correlated with blood lactate levels.

So we use lactate monitoring.